Global Onychomycosis (Tinea Unguium) Drug Market is Projected to Reach 2,905 million USD by 2022

Global Onychomycosis (Tinea Unguium) Drug Market is Projected to Reach 2,905 million USD by 2022 QYRESEARCH FOCUS ON MARKET SURVEY AND RESEARCH

www.qyresearch.com

Beijing Hengzhou Bozhi International Information Consulting Web: qyresearchglobal.com | qyresearch.com TEL:+86-13660489419, Office:+86-2086655165 Media: press@qyresearch.com Marketing: sales@qyresearchglobal.com Facebook: @QYResearchOfficial

Twitter: @QYResearch_ Wechat Official Account: QYResearch, Weibo: 恒州博智 www.qyresearch.com

QYResearch

• The Onychomycosis (Tinea Unguium) Drug industry was 2,675 million USD in 2017 and is projected to reach 2,905 million USD by 2022, at a CAGR (Compounded Annual Growth Rate) of 1.66% between 2017 and 2022. The market is driven by various end-user industries, such as Age under 18, Age 18-50 and Age above 50.

• The industry is concentration, the key brand include Johnson & Johnson, GSK, Novartis, Pfizer, Valeant Pharma, Kaken Pharmaceutical, Galderma, Xiuzheng Pharmaceutical, Letai, Qilu Pharmaceutical and so on. Among them, Johnson & Johnson and GSK are the leaders.

Click to view the full report TOC, figure and tables： https://www.qyresearch.com/index/detail/445154/globalonychomycosis-tinea-unguium-drug-market www.qyresearch.com

QYResearch

The leading companies own the advantages on better performance, more abundant product’s types, better technical and impeccable after-sales service. Consequently, they take the majority of the market share of high-end market. Looking to the future years, the slow downward price trend in recent years will maintain. As competition intensifies, prices gap between different brands will go narrowing. Similarly, there will be fluctuation in gross margin.

The industry is expected to remain innovation-led, with frequent acquisitions and strategic alliances adopted as the key strategies by the players to increase their industry presence. Market stays in mature period with a clear concentration. Meanwhile, optimize product mix and further develop value-added capabilities to maximize margins.

www.qyresearch.com

QYResearch

The Global Onychomycosis (Tinea Unguium) Drug Market Research Report 2018 report released by QYResearch provides a basic overview of the Onychomycosis (Tinea Unguium) Drug industry, including definition, classification, application and industrial chain structure. Discuss development policies and plans as well as manufacturing processes and cost structures.

The report then focuses on major industry players in Global, including company profiles, product images and specifications, sales, market share, and contact information. More importantly, the Onychomycosis (Tinea Unguium) Drug industry development trends and marketing channels were analyzed. Providing the main statistical data on the current status of the industry is a valuable guide and direction for companies and individuals interested in the market.

www.qyresearch.com

QYResearch

Request for more information@ sales@qyresearchglobal.com (use this link until we don’t have available new url for promotions) https://www.qyresearch.com/index/detail/445154/globalonychomycosis-tinea-unguium-drug-market

About Us: QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), expert’s resources (included energy automotive chemical medical ICT consumer goods etc. www.qyresearch.com

QYResearch Contact US QY Research, INC. 17890 Castleton, Suite 218, City of industry, CA - 91748 USA: +1 626 295 2442 Email – sales@qyresearchglobal.com Web – www.qyresearch.com For other region, contact number given below +86 108 294 5717 Beijing +86 208 665 5165 Guangzhou +86 215 160 1757 Shanghai +852 3062 8839 HK +1 613 366 5094 Canada +81 903 800 9273 Japan +49 176 813 78371Germany

+44 203 734 8135 UK +33 172 813 308 France +55 613 181 0478 Brazil +91 114 046 9822 India +82 704 784 4013 Korea +65 315 821 22 Singapore

www.qyresearch.com